Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... DENVER , Aug. 28, 2014 ... a two-year investment into this game-changing method for ... Today, clinical trials target specific cancers, ... be contributing factors for the cancer, in the ... is that this information may not be well ...
(Date:8/28/2014)... 28, 2014  In anticipation of the upcoming MEDevice ... available for the first time. Industry Overview: Medtech & ... offers a snapshot of San Diego,s ... from the latest employment statistics to current venture capital investment ... Diego such a vital part of the global ...
(Date:8/28/2014)... MINNEAPOLIS , Aug. 28, 2014 Nonin ... a leader in noninvasive medical monitoring, today announced that ... Nonin Model 3231 OEM/eHealth finger pulse oximeter for use ... finger pulse oximeter plugs into a telemedicine hub or ... and pulse rate in pediatric to adult patients. The ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Weiss, Director of Maryland Laser, Skin and Vein,Institute, ... BALTIMORE, Oct. 2 Robert Weiss, M.D., board ... U.S. to offer his,patients DOT Therapy (Dermal Optical ... Dr. Weiss is an,internationally renowned dermatologist, who is ...
... Biotechnologies AB and Dyax,Corp. (NASDAQ: DYAX ) ... a,collaboration to discover and to develop therapeutic ... inflammatory diseases., The collaboration follows the ... Professors Frostegard and de Faire of the ...
Cached Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4
(Date:8/28/2014)... (HealthDay News) -- A potentially deadly fungus that has ... grows on trees, a new study finds. The ... they were tipped off to the finding by a ... gattii fungus triggers infections of the lungs and ... all AIDS-related deaths, the researchers noted. They found that ...
(Date:8/28/2014)... control measures which have been adopted by most ... west Africa are unnecessary, and may heighten panic ... of a new letter, published in The Lancet ... the University of Valencia in Spain, and colleagues. ... infected patients, blood, vomit, faeces and other secretions, both ...
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the American Society for Bone and Mineral Research from ... are meant to promote the entry of students, post ... of the basic science community and to encourage the ... Bone and Mineral Research. This year MARC conferred ...
(Date:8/28/2014)... (Aug. 28, 2014) Solid-head power toothbrushes ... to researchers at The University of Texas Health ... The results of the study are published in ... Hygiene. Lead author and professor at the UTHealth ... notes that microbial counts were lower in the ...
(Date:8/28/2014)... Tampa, Florida (PRWEB) August 28, 2014 ... into the Healthbox tech accelerator program in Tampa. ... help seven innovative healthcare companies grow and achieve their ... this Tuesday, August 16th, at their launch event at ... healthcare innovation professionals. , Co-founder Matt Schneider commented on ...
Breaking Medicine News(10 mins):Health News:California Trees Harbor Fungus Deadly to People With HIV 2Health News:The Lancet: Respiratory infection controls being used for ebola patients are unnecessary and may contribute to public panic 2Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2
... become one of the major public health problems in developed ... a researcher at the University of Zaragoza (UNIZAR), tells SINC. ... than two hours of television per day. At weekends, this ... July issue of the journal Preventive Medicine , show ...
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... -- also known as cryotherapy -- works better than applying ... No one treatment cured more than half of cases, ... needed, experts say. The new finding is a bit ...
... Round Rock, Texas is recruiting patients for a Phase ... recurrence in previously treated patients. The trial will ... Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung ... Cell LunG Cancer Immunotherapy) study is expected to be ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 16 ... risk of colorectal cancer, new research finds. Prior research ... colon cancer. But this study is among the first to ... side effects such as gastrointestinal bleeding -- may also be ...
... patients develop post-traumatic stress syndrome (PTSD) after the trauma ... to be exacerbated by delusional or fragmentary memories of ... writing in BioMed Central,s open access journal Critical ... relatives make a diary for patients, featuring information about ...
... significant and lasting relief for patients with myelofibrosis, a ... University of Texas MD Anderson Cancer Center report in ... . Myelofibrosis is caused by the accumulation of ... scarring the bone marrow and limiting its ability to ...
Cached Medicine News:Health News:Teenagers are more sedentary on weekends 2Health News:For Common Warts, Freezing Therapy Works Best: Study 2Health News:For Common Warts, Freezing Therapy Works Best: Study 3Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Intensive care diaries protect patients from PTSD 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 3
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: